Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://kathrynhugk194494.wikicorrespondence.com/7267033/retatrutide_australia_a_new_hope_for_losing_weight